 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > ImmuLogic Pharmaceutical Corporation
 |
ImmuLogic Pharmaceutical Corporation |
 |
 |
 |
PROFILE |
 |
ImmuLogic Pharmaceutical thinks it's logical to get out of the drug-development business. The firm, which focused on developing drug-abuse vaccines and allergy treatments, is dissolving. Cantab Pharmaceuticals bought its research on vaccines to combat cocaine and nicotine abuse and addiction. With no products on the market, ImmuLogic relied on grants (including funding from the National Institutes of Health) and funds from collaborative agreements. Its collaborative partners included Schering AG, Hoechst Marion Roussel (now Aventis Pharmaceuticals), and Sankyo Co. The firm will stop trading on August 27, 2002, if it has not fully liquidated its assets by then. Investor Carl Icahn owns about 15% of the company.
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1998 Sales (mil.): 4.30
1-Yr. Sales Growth: 115.0%
Employees: 5
Revenue per employee: $860,000.00
KEY PEOPLE |
 |
J. Richard Crowley
CEO
CONTACT INFO |
 |
12 Alfred St., Ste. 300
Woburn, MA 01801
US
Phone: 781-933-1772
Fax: 781-933-2637
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |